Oncomfort, a Belgian startup that has come up with an innovative way to relieve patients’ pain and anxiety without medication, today announced the completion of a €10 million Series A funding round co-led by Debiopharm and Crédit Mutuel Innovation.
Founded in Wavre in 2017, Oncomfort plans to use the fresh cash to bolster its digital therapy solutions and accelerate its international expansion.
The startup calls its method ‘Digital Sedation’, which features clinically-proven therapeutic virtual reality sessions that have been used by more than 30,000 patients to date.
“We are at a tipping point in our digital therapy,” said Mario Huyghe, co-founder and chief executive officer of Oncomfort. “The medical community has discovered the advantages and potential of Digital Sedation to relieve pain and anxiety without medication. Virtual Reality acts as an enabler for this digital therapy. Yet, Oncomfort’s true potential comes from the scientific evidence of its digital sedation and the multidisciplinary co-creation with the expertise of anesthesiologists, neurologists, psychologists, and hypnotherapists.”